• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Altria Group Inc.

    5/21/25 4:43:17 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    S-8 1 s-82025pipcoverpage.htm FORM S-8 Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    ________________________________________________________________________________________________________________

    ALTRIA GROUP, INC.
    (Exact name of registrant as specified in its charter)
    ______________________________________________________________________________________________________________
    Virginia13-3260245
    (State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)
    6601 West Broad Street,Richmond,Virginia23230
    (Address of Principal Executive Offices)        (Zip Code)
    _______________________________________________________________________________________________________________

    2025 Performance Incentive Plan
    (Full title of the plan)
    _______________________________________________________________________________________________________________

    W. Hildebrandt Surgner, Jr.
    Vice President, Corporate Secretary and
    Associate General Counsel
    ALTRIA GROUP, INC.
    6601 West Broad Street
    Richmond, Virginia 23230
    (Name and address of agent for service)
    (804) 274-2200
    (Telephone number, including area code, of agent for service)
    _______________________________________________________________________________________________________________
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer x
    Accelerated filer ☐
    Non-accelerated filer ☐Smaller reporting filer ☐
    Emerging growth filer ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o






    Part I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1.        Plan Information.
    Not required to be filed with the U.S. Securities and Exchange Commission (the “Commission”).

    Item 2.        Registrant Information and Employee Plan Annual Information.
    Not required to be filed with the Commission.

    Part II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.        Incorporation of Documents by Reference.
    The following documents filed by Altria Group, Inc. (the “Company”) with the Commission (File No. 001-08940) are incorporated by reference in, and made a part of, this Registration Statement (other than documents or information included in such documents deemed to have been furnished and not filed in accordance with Commission rules):

    (i)the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (including portions of the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 3, 2025, incorporated by reference in such Annual Report on Form 10-K);

    (ii)the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025;

    (iii)the Company’s Current Reports on Form 8-K, or amendments thereto, filed with the Commission on January 30, 2025, January 30, 2025, February 6, 2025 and May 19, 2025; and

    (iv)the description of the Company’s Common Stock contained in Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, including any subsequent amendment or any report subsequently filed for the purpose of updating such description.

    All documents filed by the Company under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the date of this Registration Statement and before the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in, and to be a part of, this Registration Statement from the date of filing of such documents (other than documents or information included in such documents deemed to have been furnished and not filed in accordance with Commission rules). Any statement contained in a document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any other subsequently filed document that is incorporated by reference in this Registration Statement modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4.        Description of Securities.
    Not applicable.
    Item 5.        Interests of Named Experts and Counsel.
    Not applicable.
    Item 6.        Indemnification of Directors and Officers.
    The Virginia Stock Corporation Act (the “VSCA”) permits the Company to indemnify its directors and officers in connection with certain actions, suits and proceedings brought against them if they acted in good faith and believed their conduct to be in the best interests of the Company and, in the case of criminal actions, had no reasonable cause to believe that the conduct was unlawful. The VSCA requires such indemnification when a director or an officer entirely prevails in the defense of any proceeding to which he or she was a party because he or she is or was a director or an officer of the Company,



    and further provides that the Company may make any other or further indemnity (including indemnity with respect to a proceeding by or in the right of the Company), and may make additional provision for advances and reimbursement of expenses, if authorized by its articles of incorporation or shareholder-adopted by-laws, except an indemnity against willful misconduct or a knowing violation of the criminal law. The Company’s articles of incorporation, as amended, provide that a director or an officer or former director or officer of the Company shall be indemnified to the full extent permitted by the VSCA as currently in effect or as hereafter amended in connection with any action, suit or proceeding brought by or in the right of the Company or brought by or on behalf of shareholders of the Company.
    The VSCA establishes a statutory limit on liability of directors and officers of the Company for damages assessed against them in a suit brought by or in the right of the Company or brought by or on behalf of shareholders of the Company and authorizes the Company to specify a lower monetary limit on liability in the Company’s articles of incorporation or, with shareholder approval, by-laws; however, the liability of a director or an officer shall not be limited if such director or officer engaged in willful misconduct or a knowing violation of the criminal law or of any federal or state securities law. The Company’s articles of incorporation, as amended, provide for the limitation or elimination of the liability of a director or an officer or former director or officer of the Company for monetary damages to the Company or its shareholders in any action, suit or proceeding, to the full extent permitted by the VSCA as currently in effect or as hereafter amended. The Company carries insurance on behalf of its directors and officers.
    The distribution agreement among the Company, the Company’s wholly-owned subsidiary, Philip Morris USA Inc. and Philip Morris International Inc. (“PMI”) provides for indemnification by PMI of the Company’s directors, officers and employees for certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act, related to information provided to the Company by PMI or incorporated into filings by the Company from PMI’s filings with the Commission.
    The Company has entered into an indemnity agreement with each of the members of its Board of Directors (the “Board”). The agreement provides for the mandatory advancement and reimbursement of reasonable expenses (subject to limited exceptions) incurred by the members of the Board in various legal proceedings in which they may be involved by reason of their service as directors, as permitted by Virginia law and the Company’s articles of incorporation.

    Item 7.        Exemption from Registration Claimed.
    Not applicable.

    Item 8.        Exhibits.
    Exhibit No.Description
    5
    Opinion of McGuireWoods LLP as to the legality of the securities being registered (filed herewith).
    23.1Consent of McGuireWoods LLP (included in Exhibit 5).
    23.2
    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm (filed herewith).
    24
    Powers of Attorney executed by Ian L.T. Clarke, Marjorie M. Connelly, R. Matt Davis, Debra J. Kelly-Ennis, Kathryn B. McQuade, George Muñoz, Virginia E. Shanks, Richard S. Stoddart, Ellen R. Strahlman and M. Max Yzaguirre (filed herewith).
    99
    2025 Performance Incentive Plan (incorporated by reference to Exhibit A to the Company’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 3, 2025 (File No. 1-08940)).
    107
    Filing Fee Table (filed herewith).

    Item 9.        Undertakings.
    (a) The undersigned registrant hereby undertakes:
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement.



    Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” table in the effective Registration Statement; and
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change in such information in this Registration Statement;
    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to provisions described in Item 6 above, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Henrico, Commonwealth of Virginia, on May 21, 2025.


    ALTRIA GROUP, INC.
    By:/s/ SALVATORE MANCUSO
    (Salvatore Mancuso
    Executive Vice President and
    Chief Financial Officer)

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on May 21, 2025.
    SignatureTitle
    /s/ WILLIAM F. GIFFORD, JR.Director and Chief Executive Officer
    (Principal Executive Officer)
    (William F. Gifford, Jr.)
    /s/ SALVATORE MANCUSOExecutive Vice President and Chief Financial Officer
    (Principal Financial Officer)
    (Salvatore Mancuso)
    /s/ STEVEN D’AMBROSIAVice President and Controller
    (Principal Accounting Officer)
    (Steven D’Ambrosia)
    * IAN L.T. CLARKE,Directors
    MARJORIE M. CONNELLY,
    R. MATT DAVIS,
    DEBRA J. KELLY-ENNIS,
    KATHRYN B. MCQUADE,
    GEORGE MUÑOZ,
    VIRGINIA E. SHANKS,
    RICHARD S. STODDART,
    ELLEN R. STRAHLMAN,
    M. MAX YZAGUIRRE

    *By:
    /s/ WILLIAM F. GIFFORD, JR.
    (WILLIAM F. GIFFORD, JR.
    ATTORNEY-IN-FACT)

    Get the next $MO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    11/10/2022$38.00Neutral → Sell
    UBS
    6/29/2022$53.00 → $36.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

      5/15/25 1:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria to Host Webcast of 2025 Annual Meeting of Shareholders

      Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast of its 2025 Annual Meeting of Shareholders ("2025 Annual Meeting" or "meeting") on Thursday, May 15, 2025 at 9:00 a.m. Eastern Time. The 2025 Annual Meeting will be held virtually via live webcast. During the meeting, shareholders as of the 2025 Annual Meeting record date (March 25, 2025) will be able to vote their shares electronically and will be able to submit questions during the meeting as time permits. Although shareholders will be able to vote their shares during the meeting, they are encouraged to do so before the meeting using one of the methods described in the 2025 Proxy Statement. If you are not a shareholder

      5/1/25 10:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yzaguirre Mario Max was granted 3,219 shares, increasing direct ownership by 25% to 16,252 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:06:43 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Strahlman Ellen R was granted 3,219 shares, increasing direct ownership by 16% to 23,087 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:05:17 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Stoddart Richard S was granted 3,219 shares (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:03:40 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Altria downgraded by Deutsche Bank

      Deutsche Bank downgraded Altria from Buy to Hold

      4/1/25 3:04:54 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Morgan Stanley initiated coverage on Altria with a new price target

      Morgan Stanley initiated coverage of Altria with a rating of Equal-Weight and set a new price target of $54.00

      1/16/25 7:47:52 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria upgraded by BofA Securities with a new price target

      BofA Securities upgraded Altria from Neutral to Buy and set a new price target of $65.00 from $55.00 previously

      12/6/24 7:56:47 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/13/24 4:58:48 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/13/23 2:49:28 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/9/23 10:54:46 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    See more
    • Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

      Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

      2/26/24 4:30:00 PM ET
      $ARIS
      $MO
      $PXD
      Oilfield Services/Equipment
      Energy
      Medicinal Chemicals and Botanical Products
      Health Care
    • Seasoned Financial Expert Max Yzaguirre Named Strategic Advisor of FireFly Automatix, Leader in AV and EV-Driven Professional Turfgrass Mowing Technology

      -Yzaguirre joins a list of seasoned professionals on FireFly's team with specific expertise in initiating and growing businesses in evolving market conditions- FireFly Automatix, Inc., the de facto industry leader in AV and EV professional turfgrass mowing technology, today announced the appointment of financial and leadership expert M. Max Yzaguirre as a strategic advisor to CEO Andrew Limpert and the board of directors. Yzaguirre's appointment follows the recent additions of former WPP Group CFO Paul Richardson and capital markets professional Liz Hocker to FireFly's board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202401

      1/23/24 9:00:00 AM ET
      $ARIS
      $LBC
      $MO
      Oilfield Services/Equipment
      Energy
      Major Banks
      Finance
    • Altria Group, Inc. Announces Retirement of Director Nabil Y. Sakkab From Board of Directors

      Nabil Y. Sakkab, a director of Altria Group, Inc. ("Altria") since 2008, will retire from service on our Board of Directors following the completion of his current term. Consequently, Mr. Sakkab will not stand for re-election to the Board of Directors at Altria's 2024 Annual Meeting of Shareholders, which Altria anticipates holding on May 16, 2024. "Nabil's contributions have significantly benefited Altria over the past 15 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank him for his long and distinguished service and wish him the very best upon his retirement." Dr. Sakkab is Chair of the Innovation Committee and is a member of the Executive, Finance, and

      10/25/23 4:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Financials

    Live finance-specific insights

    See more
    • Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

      5/15/25 1:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.02 per share, payable on April 30, 2025 to shareholders of record as of March 25, 2025. The ex-dividend date is March 25, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250227441410/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

      2/27/25 3:00:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    SEC Filings

    See more
    • SEC Form S-8 filed by Altria Group Inc.

      S-8 - ALTRIA GROUP, INC. (0000764180) (Filer)

      5/21/25 4:45:53 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 filed by Altria Group Inc.

      S-8 - ALTRIA GROUP, INC. (0000764180) (Filer)

      5/21/25 4:43:17 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

      5/19/25 8:41:28 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:08:44 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:03:21 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care